Dr. Jerome Kim

Director General
International Vaccine Institute

Jerome H. Kim, M.D., is an international expert on the development and evaluation of vaccines and is the Director General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective and affordable vaccines for Global Health. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease.  IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience received regulatory approval in the Republic of Korea (May 2022) and to PT Bio Farma, Indonesia (approval expected in 2022). 

IVI’s work with companies developing COVID-19 vaccines may contribute 1.2 billion doses to the global COVAX facility – providing COVID-19 vaccines for people in low- and middle-income countries. Prior to IVI, he was the Principal Deputy, US Military HIV Research Program and Chief, Laboratory of Molecular Virology and Pathogenesis at the Walter Reed Army Institute of Research, and the US Army Program Manager for HIV Vaccines.  He led the Army’s RV144 Phase III HIV vaccine trial that showed efficacy in the prevention of HIV-1. Dr. Kim is an Adjunct Professor of Medicine at the Uniformed Services University, USA, and at Yonsei University Graduate School of Public Health and a Distinguished Visiting Professor at Seoul National University, Korea.

He has authored over 300 publications. He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology and received his M.D. from the Yale University School of Medicine. Dr. Kim has received numerous awards: John Maher Award for Research Excellence, USUHS, 2013; Department of the Army Research and Development Achievement Award for Technical Excellence, 2013; Asia Pacific Vaccine Excellence Lifetime Achievement Award, 2021; Medal of Honor for Civil Merit from the Korean government, 2022.